2-Aminoethoxydiphenylborate (2-APB) inhibits release of phosphatidylserine-exposing extracellular vesicles from platelets

Hao Wei1, Jessica E. Davies1 and Matthew T. Harper1

Abstract
Activated, procoagulant platelets shed phosphatidylserine (PS)-exposing extracellular vesicles (EVs) from their surface in a Ca2+ and calpain-dependent manner. These PS-exposing EVs are prothrombotic and proinflammatory and are found at elevated levels in many cardiovascular and metabolic diseases. How PS-exposing EVs are shed is not fully understood. A clearer understanding of this process may aid the development of drugs to selectively block their release. In this study we report that 2-aminoethoxydiphenylborate (2-APB) significantly inhibits the release of PS-exposing EVs from platelets stimulated with the Ca2+ ionophore, A23187, or the pore-forming toxin, streptolysin-O. Two analogues of 2-APB, diphenylboronic anhydride (DPBA) and 3-(diphenylphosphino)-1-propylamine (DP3A), inhibited PS-exposing EV release with similar potency. Although 2-APB and DPBA weakly inhibited platelet PS exposure and calpain activity, this was not seen with DP3A despite inhibiting PS-exposing EV release. These data suggest that there is a further target of 2-APB, independent of cytosolic Ca2+ signalling, PS exposure and calpain activity, that is required for PS-exposing EV release. DP3A is likely to inhibit the same target, without these other effects. Identifying the target of 2-APB, DPBA and DP3A may provide a new way to inhibit PS-exposing EV release from activated platelets and inhibit their contribution to thrombosis and inflammation.

Introduction
Platelets are the main cellular component of haemostasis. They adhere, activate and aggregate at sites of vascular injury, forming a haemostatic plug that prevents blood loss. However, platelet activation on a ruptured coronary atherosclerotic plaque is the main event in coronary thrombosis, leading to unstable angina or myocardial infarction. Anti-platelet drugs are therefore used to prevent coronary thrombosis in at-risk patients.

During platelet activation, procoagulant platelets expose phosphatidylserine (PS) in the outer leaflet of their plasma membrane. PS is normally restricted to the inner leaflet by an aminophospholipid translocase (‘flipase’). A high, sustained increased in cytosolic Ca2+ concentration (\([\text{Ca}^{2+}]_{\text{cyt}}\)) leads to inhibition of the flipase and activation of a non-selective phospholipid scramblase, TMEM16F4–6. The result is net movement of PS to the outer leaflet. PS forms a procoagulant surface for the tenase and prothrombinase coagulation complexes, increasing thrombin generation.

Procoagulant platelets also release PS-exposing extracellular vesicles (EVs). These are prothrombotic and proinflammatory. The levels of PS-exposing EVs are increased in many cardiovascular and metabolic disorders, and platelets are the major source of circulating PS-exposing EVs. The pathological role of PS-exposing EVs, and their elevation in a range of diseases, makes them an attractive therapeutic target.

How PS-exposing EVs are shed from the plasma membrane is not fully understood. A clearer understanding of this process may aid the development of drugs to selectively block their release. PS exposure itself may be important, as they are not shed from platelets from Tmem16f−/− mice or from patients with Scott Syndrome, a very rare bleeding disorder caused by...
lack of functional TMEM16F5,19. In addition, high [Ca2+]cyc, in procoagulant platelets activates the Ca2+-dependent protease, calpain20,21. Calpain-dependent cleavage of cytoskeletal proteins is also necessary. However, little is known of the mechanism beyond these events. Indeed, it is not clear whether any events other than PS exposure and calpain activity are required downstream of increased [Ca2+]cyc.

Platelets can be effectively stimulated to shed PS-exposing EVs by Ca2+ ionophores, such as A23187, triggering a high, sustained increase in [Ca2+]cyc. Although not a physiological stimulus, by bypassing platelet receptors and their proximal signalling cascades it can be used to understand the downstream mechanisms of EV release. PS-exposing EVs can be distinguished by their size and their capacity to bind annexin V (AnV). During preliminary experiments, we were surprised to find that 2-aminoethoxydiphenylborate (2-APB) significantly inhibited A23187-induced annexin V-positive (AnV+) EV release. This was surprising since 2-APB is a cell-permeable modulator of numerous ion channels, particularly Ca2+ channels, yet we expected the use of a Ca2+ ionophore to bypass any contribution of plasma membrane or intracellular Ca2+ channels. Therefore, in this study, we investigated the mechanism of how 2-APB inhibits the release of AnV+ EVs from platelets. We find that the effect of 2-APB does not depend on inhibition of Ca2+ signalling, PS exposure or calpain activity. These results indicate that events in addition to PS and calpain activation are required for release of PS-exposing EVs and suggest the existence of other potential targets to inhibit this important pathological process.

**Results**

**2-APB inhibits AnV+ EV release induced by the Ca2+ ionophore, A23187**

In order to better understand the processes by which platelets release PS-exposing EVs, platelets were stimulated with the Ca2+ ionophore, A23187. This triggers rapid Ca2+ entry, resulting in PS exposure and release of PS-exposing EVs. PS exposure was detected using annexin V (AnV) (Fig. 1a). AnV+ platelets and AnV+ EVs were detected by flow cytometry. As we have previously discussed, this approach is likely to preferentially detect the largest AnV+ EVs and to underestimate the total number of EVs released22. However, it is still a rapid and effective means of assessing AnV+ EV release.

Pre-treatment with 2-APB (100 µM) significantly inhibited AnV+ EV release compared to platelets treated with the vehicle (DMSO) at all concentrations of A23187 tested. In contrast, the percentage of AnV+ platelets was only weakly affected (Fig. 1a–c). When 10 µM A23187 was used, 2-APB inhibited AnV+ EV release with a pIC50 of 4.45 ± 0.09 (IC50 approximately 35 µM; n = 5), with no corresponding effect on platelet AnV+ binding (Fig. 1d).

To assess the reversibility of the inhibition, platelets were treated with 2-APB or DMSO then washed by centrifugation. The procedure of washing platelets by centrifugation resulted in slightly greater sensitivity to A23187 (pEC50 of 5.77 ± 0.20 for AnV+ EV release prior to washing; pEC50 of 6.16 ± 0.12 after washing). 2-APB-treated platelets released significantly fewer AnV+ EVs when stimulated with A23187. Notably, there was now no difference in platelet AnV binding between 2-APB-treated and DMSO-treated platelets at any concentration of A23187 (Supplementary Fig. 1).

Together, these data indicate that 2-APB inhibits A23187-induced AnV+ EV release. This action not related to the weak inhibition of platelet PS exposure.

**Structural analogues of 2-APB show differing effects on AnV+ EV release**

2-APB has many reported targets. To further characterise its effects, we used a small panel of related, commercially available compounds (Supplementary Fig. 2). The effects of these analogues on some 2-APB targets has been previously described (Supplementary Table 1).

Some analogues had no effect on A23187-induced AnV+ EV release (Fig. 2). Phenylboronic acid (PBA) has the boron atom attached to only one phenyl group and may be too simple a fragment to effectively inhibit AnV+ EV release. Since di-PBA is unstable23, we used the more stable analogue, dimestyboronic acid (DMBA), which has two phenyl rings replaced by mesityl groups. This was also ineffective at 100 µM. It may be that analogues with a terminal B–OH are ineffective and that a B–O core is required.

Two analogues that lack the boron atom were also ineffective: 2,2-diphenyltetrahydrofuran (DPTHF), which has a five-membered ring containing an oxygen atom, similar to the ring form of 2-APB, but lacks a boron or nitrogen atom, and diphenhydramine (DPHD), which is similar to the linear form of 2-APB, but lacks the boron atom and has two methyl groups attached to the secondary amine.

In contrast, diphenylboronic anhydride (DPBA) and 3-(diphenylphosphino)-1-propylamine (DP3A) both inhibited AnV+ EV release. Both were of similar potency to 2-APB. The pIC50 for DPBA was 4.55 ± 0.32 (IC50 approximately 28 µM; n = 5). The pIC50 for DP3A was 4.38 ± 0.14 (IC50 approximately 42 µM; n = 5). The effectiveness of DPBA and DP3A indicates that neither the amine group nor the boron atom is necessary for inhibition. In addition, DPBA partially reduced the percentage of AnV+ platelets, whereas DP3A did not, suggesting that the boron atom may be important for this weak inhibition.
Fig. 1 (See legend on next page.)
The inhibitory effect of 2-APB is not through inhibition of Ca²⁺ signalling

2-APB is known to modulate a variety of plasma membrane channels that are expressed in platelets, including Orai1, TRPC6 and Ca²⁺-activated K⁺ channels. To determine whether any of these targets were involved in the inhibitory effect of 2-APB, Cal-520-loaded platelets were used to monitor the effect of A23187 and 2-APB on cytosolic Ca²⁺ signalling. A23187 induced a rapid increase in fluorescence (Fig. 3a). Surprisingly, 2-APB inhibited this increase in fluorescence in a concentration-dependent manner (Fig. 3a, b). Although DPBA also inhibited the Cal-520 fluorescence in a concentration-dependent manner, DP3A had no effect (Fig. 3a, b). This is important as DP3A inhibited AnV⁺ EV release, suggesting that there is no direct link between the inhibition of Cal-520 fluorescence and inhibition of AnV⁺ EV release. The analogues that did not affect AnV⁺ EV release (PBA, DPTHF, DPHD, and DMBA) had no effect on the A23187-induced increase in fluorescence (Fig. 3c).

Inhibition of Orai1 with Synta-66 (10 μM), TRPC6 with SAR-7334 (1 μM) or the Na⁺-Ca²⁺ exchanger (NCX) with SN-6 (50 μM), singly or combined, had no effect on the A23187-induced increase in Cal-520 fluorescence, AnV⁺ EV release or platelet AnV binding (Fig. 3d–f).

Since it was surprising that 2-APB affected A23187-induced cytosolic Ca²⁺ signalling, we investigated whether the effect on Cal-520 fluorescence might be an artefact owing to a change in cytosolic pH. Addition of NH₄Cl to unstimulated Cal-520-loaded platelets, which is expected to result in rapid intracellular alkalinisation, gave a rapid increase in fluorescence. Similarly, addition of extracellular NaOH also increased the fluorescence. Extracellular HCl had little effect on the Cal-520 fluorescence in unstimulated platelets (Fig. 4a). Although A23187 rapidly increased Cal-520 fluorescence to a plateau, which is as expected as the dye is likely to be saturated with Ca²⁺ under these conditions, this fluorescence could be further increased by extracellular NH₄Cl or NaOH. It could also be decreased by extracellular HCl, suggesting that H⁺ enters stimulated platelets (Fig. 4b). Together, these data show that Cal-520 fluorescence is highly sensitive to pH.
Fig. 2 Structural analogues of 2-APB show differing effects on AnV⁺ EV release. 

**a, b** Platelets were treated with the indicated analogue (100 µM; 30 min), or DMSO as control, then stimulated with a concentration range of A23187. AnV⁺ EV release and platelet AnV binding were determined as described in Fig. 1. Concentration–response curves were fitted with a four-parameter logistic equation. Data were further analysed by two-way RM-ANOVA with Sidak’s post-test. *p < 0.05; **p < 0.01; ***p < 0.001 for comparison with DMSO-treated platelets. For clarity, in the right-hand panel, statistical significance for DP3A is marked with † (††p < 0.01; †††p < 0.001) but also indicates comparison with DMSO-treated platelets. **c, d** Platelets were treated with a concentration range of DPBA (c) or DP3A (d) prior to stimulation with A23187 (10 µM).
Fig. 3 2-APB, DPBA and DP3A reduce Cal-520 fluorescence. a Representative traces of Cal-520-loaded platelets treated as indicated then stimulated with A23187 (10 µM; black arrowhead), expressed as Cal-520 fluorescence normalised to the fluorescence prior to stimulation (F/F₀).

b Mean (±s.e.m.; n = 5) of maximum F/F₀ in each condition, as a percentage of DMSO-treated platelets. c Maximum F/F₀ for the inactive analogues (line indicated mean).

d Cal-520-loaded platelets were treated with SAR-7334 (1 µM), SN-6 (50 µM) and Synta-66 (10 µM), individually or combined, as indicated, before stimulation with A23187 (10 µM; black arrowhead). The traces are representative of five independent experiments.

e, f AnV⁺ EV release and platelet AnV binding in samples treated with these inhibitors. No statistically significant difference was observed compared to platelets treated with the solvent, DMSO (in each, one-way RM-ANOVA; n = 5).
active drugs inhibited calcein loss from SL–O-permeabilised platelets (Fig. 5e).

2-APB and DPBA partially inhibits calpain activation, but DP3A does not

Calpain is required for AnV⁺ EV release following A23187 or SL–O treatment. Platelet stimulation with A23187 resulted in cleavage of the calpain substrates, talin, ATP8A1, PTP1C and caspase-3, which was prevented by pre-treatment with calpeptin (Fig. 6a). For example, A23187 reduced the presence of the highest talin band to 8.5 ± 3.4% of unstimulated (DMSO-treated) samples ($n = 5$), whereas in the presence of calpeptin, this band was not significantly changed to 96.7 ± 6.1% of
Fig. 5 (See legend on next page.)
unstimulated, calpeptin-treated samples. Likewise, stimulation with A23187 led to the presence of a lower band (approximately 30 kDa) detected by the anti-caspase-3 antibody, consistent with previous reports. However, in calpeptin-treated samples, stimulation of A23187 led to a barely detectable band, only 4.4 ± 1.0% (n = 5) of the band in DMSO-treated, A23187-stimulated samples. 2-APB (100 µM) also partially inhibited the cleavage of these substrates. In 2-APB-treated samples, D23187 reduced the highest band to 57.0 ± 11.0% compared to DMSO, unstimulated samples (p < 0.05; also p < 0.05 compared to DMSO, A23187-stimulated; one-way ANOVA with Tukey’s multiple comparisons test). Similarly, in 2-APB-treated samples, the lower caspase-3 band was only 40.8 ± 8.3% of that in DMSO-treated, A23187-stimulated samples (p < 0.05; n = 5). The 2-APB analogues were then tested for their ability to prevent the cleavage of two of these substrates, talin and caspase-3. Of the 2-APB analogues tested, DPBA also partially inhibited the cleavage of talin and caspase-3, but DP3A, PBA, DMBA, DPHD and DPTHF had no effect (Fig. 6b).

2-APB also inhibits AnV⁺ EV release from endothelial cells

To determine whether the inhibitory effect of 2-APB was restricted to platelets, human umbilical vein endothelial cells (HUVECs) were stimulated with A23187 (10 µM), resulting in AnV⁺ binding to HUVECs and release of AnV⁺ EVs (Fig. 7a). AnV⁺ EV release was prevented by calpeptin, indicating that it is dependent on calpain activity (Fig. 7a). Pre-treatment with 2-APB (100 µM) inhibited the release of AnV⁺ EVs but not HUVEC AnV binding. The pIC50 for inhibition of AnV⁺ EV release was 5.88 ± 0.21 (Fig. 7d; n = 5), showing that 2-APB is more potent in HUVECs than platelets. The same range of 2-APB analogues was then tested (Fig. 7b, c). PBA unexpectedly increased AnV⁺ EV release. DMBA caused a significant loss of HUVEC viability, which may explain the increase in AnV⁺ EV release that it caused, and was not used further (Fig. 7c). AnV⁺ EV release was inhibited by DPBA (Fig. 7f; pIC50 = 6.03 ± 0.11; n = 5) and DP3A (Fig. 7e; pIC50 = 5.52 ± 0.32), as in platelets. However, in contrast to platelets, DPTHF also inhibited AnV⁺ EV release (Fig. 7g; pIC50 = 5.68 ± 0.20). DPHD also inhibited AnV⁺ EV release, but only at 100 µM. These data suggest that the pharmacology of AnV⁺ EV release from HUVEC is similar, but not identical, to that of platelets.

Discussion

PS-exposing EVs released by activated platelets are prothrombotic and proinflammatory, and so inhibiting their release may be a beneficial therapeutic approach. However, little is known about the mechanisms that lead to their release and there are few drugs that can selectively inhibit this process. In this study, we demonstrate that 2-APB, a widely used Ca²⁺ channel modulator, inhibits PS-exposing EV release. This is not through inhibition of the major pathways currently known to be required for release of PS-exposing EVs and is not through inhibition of currently known targets of 2-APB. Although 2-APB itself is insufficiently selective or potent to be a useful therapeutic inhibitor of EV release, our results suggest the existence of a potential target. Future identification of this target may aid the development of therapeutic drugs that prevent the release of PS-exposing EVs.

Although little is known about the mechanisms of PS-exposing EV release from activated platelets, it requires a high, sustained increase in [Ca²⁺]cyt and a Ca²⁺ ionophore. Although this is not a physiological stimulation, it should bypass intracellular Ca²⁺ release channels, such as IP₃Rs, and plasma membrane Ca²⁺ entry channels, such as Orai1 and TRPC6, major targets for 2-APB in platelets. Indeed, this is why we were not expecting 2-APB to inhibit A23187-induced release of AnV⁺ EVs. In contrast, if physiological activators were used, such as thrombin plus cross-linked collagen-related peptide, the increase in [Ca²⁺]cyt would require these Ca²⁺ channels. The multiple effects of 2-APB mean that it would not itself be a suitable therapeutic, although understanding its mechanism of action may help us to understand the mechanisms that underlie the release of PS-exposing EVs from platelets.
Increased $[\text{Ca}^{2+}]_{\text{cyt}}$ activates the $\text{Ca}^{2+}$-dependent scramblase, TMEM16F, leading to PS exposure, and activation of the protease, calpain. Both events are required for PS-exposing EV release. It is not likely that 2-APB directly inhibits TMEM16F, as platelet AnV binding was largely unaffected under conditions where AnV$^+$ EV release was completely inhibited. Moreover, although a small inhibition of platelet AnV binding was observed when 2-APB was present, this was fully reversed by washing the platelets, whereas the inhibition of AnV$^+$ EV release was not so readily reversed.

Since 2-APB has many identified targets, we characterised a small set of related molecules that might have differing pharmacology. Two analogues, DPBA and DP3A, retained efficacy with similar potency to 2-APB. The other analogues showed no inhibitory action at 100 µM in platelets. These observations indicated that neither the secondary amine, nor the boron atom, are absolutely required for the inhibitory action. They also suggest that the effect of 2-APB is not through inhibition of store-operated $\text{Ca}^{2+}$ entry (SOCE), since DPTHF and DMBA (and to a small extent DPHD) have been shown to...
Fig. 7 (See legend on next page.)
inhibit SOCE\textsuperscript{39} but had no effect on AnV\textsuperscript{+} EV release. Interestingly, the pattern of active and inactive analogues was similar to that reported for interleukin (II)-1β release from mouse macrophages\textsuperscript{40} (see Supplementary Table 1). In that study the effect was attributed to inhibition of the NLRP3 inflammasome. However, since II-1β may be released in EVs\textsuperscript{41}, inhibition of EV release could contribute to the inhibition of II-1β release.

Moreover, these analogues provided a small toolkit to help explore the mechanism of action of 2-APB. AnV\textsuperscript{+} EV release showed the same pattern of sensitivity to 2-APB analogues whether the process was triggered by A23187 in intact platelets or by Ca\textsuperscript{2+} addition to SL–O-permeabilised platelets. This supports the assumption that the two stimuli were triggering the same process. It also indicates that the lack of action of PBA, DMBA, DPHD and DPTHF was not due to insufficient plasma membrane permeability.

2-APB is unlikely to inhibit AnV\textsuperscript{+} EV release through an action on Ca\textsuperscript{2+} channels. This is shown by several lines of evidence. The most direct evidence is the observation that 2-APB also inhibited AnV\textsuperscript{+} EV release from SL–O-permeabilised platelets. SL–O permeabilisation allowed calcein to completely leak from the platelets, and has been previously used to introduce antibodies into platelets\textsuperscript{42}. Extracellular Ca\textsuperscript{2+} rapidly triggered AnV\textsuperscript{+} EV release from SL–O-permeabilised platelets in a calpain-dependent manner. Together, these data indicate that there is direct continuity between the extracellular and intracellular environment. 2-APB did not prevent calcein leakage from SL–O-permeabilised platelets, indicating that it did not affect this continuity. Therefore, it is unlikely that 2-APB inhibits AnV\textsuperscript{+} EV release by inhibiting Ca\textsuperscript{2+} flux between the extracellular and intracellular environment. Consistent with this conclusion, inhibition of Orai1 or TRPC6 (or NCX, which acts in reverse-mode downstream of TRPC6\textsuperscript{27}) did not affect AnV\textsuperscript{+} EV release. Moreover, it is unlikely that other ion fluxes, such as Na\textsuperscript{+}, K\textsuperscript{+} or Cl\textsuperscript{−} are required. For example, Ca\textsuperscript{2+}-activated K\textsuperscript{+} channels have previously been proposed to regulate platelet PS exposure and subsequent AnV\textsuperscript{+} EV release\textsuperscript{29}, and these channels may be inhibited by 2-APB\textsuperscript{28}. However, not only is it unlikely that K\textsuperscript{+} flux plays an important role once the platelets have been permeabilised, but also two unrelated, non-selective blockers of Ca\textsuperscript{2+}-activated K\textsuperscript{+} channels had no effect on A23187-induced AnV\textsuperscript{+} EV release. Therefore, it is likely that 2-APB has a target in AnV\textsuperscript{+} EV release that is separate to plasma membrane ion channels.

At first sight, our observation that 2-APB inhibits the A23187-induced increase in Cal-520 fluorescence appears to lead to the opposite conclusion, as it suggests that 2-APB inhibits the increase in [Ca\textsuperscript{2+}]\textsubscript{cyt}. It is unclear whether this is a real inhibition of [Ca\textsuperscript{2+}]\textsubscript{cyt}, or an artefactual effect on Cal-520 fluorescence. It is possible that 2-APB and DPBA affect the fluorescence spectrum of Cal-520 (in a manner that DP3A does not). We first considered whether 2-APB might induce cytosolic acidification, as it has been previously shown to rapidly acidify Jurkat T cells\textsuperscript{43}, though this required action on (unidentified) membrane proteins and may be a cell-type specific effect. Many Ca\textsuperscript{2+}-sensitive fluorescent dyes are acutely sensitive to pH and our data show that Cal-520 is also sensitive to pH. However, 2-APB did not affect intracellular pH, assessed by BCECF fluorescence, suggesting that cytosolic acidification does not explain the reduced Cal-520 fluorescence. In addition, treatments that did alter intracellular pH (extracellular addition of NH\textsubscript{4}Cl or HCl) did not affect AnV\textsuperscript{+} EV release. This indicates that 2-APB does not inhibit AnV\textsuperscript{+} EV release by altering intracellular pH.

It is possible that 2-APB does inhibit the A23187-induced increase in [Ca\textsuperscript{2+}]\textsubscript{cyt}, rather than artefactually decrease Cal-520 fluorescence, though the mechanisms that could be involved are unclear. The ionophore action of A23187 itself could be directly inhibited, which could be tested by using alternative approaches to increase [Ca\textsuperscript{2+}]\textsubscript{cyt} (e.g. ionomycin, thapsigargin). Our data indicate that the action of 2-APB on A23187-induced Cal-520 fluorescence does not involve inhibition of Orai1 or TRPC6, the major Ca\textsuperscript{2+} entry channels in platelets. One possibility is that platelets contain two intracellular Ca\textsuperscript{2+} stores, the dense tubular system and acidic Ca\textsuperscript{2+} stores, such as lysosomes\textsuperscript{43}. The latter are relatively insensitive to Ca\textsuperscript{2+} ionophores\textsuperscript{45} and may require a 2-APB-sensitive process for their depletion. Inhibition of [Ca\textsuperscript{2+}]\textsubscript{cyt} signalling could account for the weak inhibition of PS.
exposure and calpain activity by 2-APB and DPBA. Although PS exposure and calpain activity are required for PS-exposing EV release, these small inhibitory effects cannot account for the inhibition of AnV+ EV release by 2-APB, since the phosphorus-containing analogue, DP3A, had no effect on Cal-520 fluorescence, platelet AnV binding or calpain activity, yet inhibited AnV+ EV release with similar potency. These data suggest that there is a further target of 2-APB, independent of [Ca2+]cyt, PS exposure and calpain activity, that is required for AnV+ EV release (Fig. 8). DP3A is likely to inhibit the same target, without these other effects, and may be a better scaffold from which to develop a more selective inhibitor of EV release.

To determine whether the action of 2-APB was specific to AnV+ EV release from platelets, we also examined AnV+ EV release from HUVECs. Again, we used A23187 to directly increase [Ca2+]cyt, aiming to bypass any inhibition of Ca2+ channels by 2-APB. Endothelial cells release EVs during activation and apoptosis. Whether the mechanisms underlying the release of EVs under these different conditions are the same is unclear. In our experimental setting, A23187 rapidly triggered AnV binding to HUVEC and release of AnV+ EVs. The latter was blocked by 2-APB. However, although AnV+ EV release from HUVEC was also inhibited by DPBA and DP3A, as in platelets, these drugs were more potent in HUVEC than in platelets. Moreover, AnV+ EV release from HUVEC was also inhibited by DPTHF. This suggests that the target of 2-APB in HUVEC and platelets may be similar but are not identical. As a tentative speculation, it may involve different isoforms of a protein family. This difference opens the possibility of being able to selectively inhibit PS-exposing EV release from different cells.

Conclusion

PS-exposing EVs are released by stimulated platelets in a Ca2+/calpain-dependent manner. Although PS-exposing EVs are likely to contribute to a range of prothrombotic and proinflammatory diseases, there are few drugs available to block their release. 2-APB inhibits the release of AnV+ EVs. Identifying the target of 2-APB, DPBA and DP3A may provide a new way to inhibit AnV+ EV release from activated platelets and inhibit their contribution to thrombosis and inflammation.

Methods

Washed platelet preparation

Blood was drawn by venipuncture into sodium citrate (3.2% v/v) from healthy, drug-free volunteers, who had given written, informed consent in accordance with the Declaration of Helsinki. Use of human blood for these experiments was approved by the Human Biology Research Ethics Committee, University of Cambridge. Acid citrate dextrose (ACD; 85 mM tri-sodium citrate, 71 mM citric acid, 111 mM D-glucose) was added (1:7 v/v) and platelet-rich plasma (PRP) separated by centrifugation (200g, 10 min). Prostaglandin F12 (100 nM) and apyrase (Grade VII; 0.02 U/ml) were added to PRP to prevent platelet activation during preparation. Where required, platelets were incubated with either Cal-520-acetoxyethyl (AM) or calcein-AM (both 2 µM; 10 min). Platelets were pelleted from PRP by centrifugation (600g, 10 min) and resuspended in HEPES-buffered saline (in mM: 10 HEPES, 135 NaCl, 3 KCl, 0.34 NaH2PO4, 1 MgCl2, 6H2O, pH 7.4; supplemented with 0.9 mg/ml D-glucose) at 5 x 107 platelets/ml. Platelets were rested (30 °C, 30 min) prior to treatment with inhibitors or stimulation. CaCl2 (2 mM) was added immediately prior to simulation.

Flow cytometry analysis

Following stimulation, samples were stained with FITC-conjugated annexin V (eBioscience, ThermoFisher, UK), to detect exposed PS, (FL1), unless otherwise indicated, and PE-Cy7-conjugated anti-CD41 antibody (eBioscience, ThermoFisher, UK), to distinguish platelet-derived events. Samples were analysed using a BD Accuri C6 flow cytometer. PE-Cy7 fluorescence (FL3) was used to trigger event acquisition. PS-positive platelet-derived EVs were defined as CD41+/annexin V+ events that were smaller than 1 µm. The 1 µm gate was set in forward scatter using 1 µm silica beads.

Immunoblotting

Platelet proteins were detected in platelet lysates by sodium dodecyl sulfate–polyacrylamide gel electrophoresis.
and immunoblotting, essentially as described previously. The primary antibodies used were: anti-talin antibody (clone 8D4; T3287; from Sigma Aldrich, Poole, Dorset, UK) anti-PTP1C (610125; BD Biosciences); anti-ATP8A1 (clone 8D4; T3287; from Sigma Aldrich, Poole, Dorset, UK) and anti-caspase3 (9662) and anti-GAPDH (2118; from Cell Signalling Technology; Davers MA, USA). The secondary antibodies used were horseradish peroxidase-conjugated anti-rabbit IgG (7074) or anti-mouse IgG (7076; both Cell Signalling Technology).

**Measurement of cytosolic Ca^{2+} concentration ([Ca^{2+}]_{cyt}) and pH**

Cal-520-loaded platelets were stimulated in black-walled microplates at 30 °C. Fluorescence (excitation: 492 nm; emission: 520 nm) was recorded using a FLUOSStar OMEGA (BMG LabTech). BCECF-loaded platelets were stimulated in black-walled microplates at 30 °C. Fluorescence (excitation: 485 nm; emission: 520 nm).

**Measurement of endothelial EV release and PS exposure**

HUVEC (Promocell, c-12203), were cultured in endothelial cell growth medium (PromoCell, c-22010), supplemented with 35 μg/mL gentamycin and endothelial cell growth supplements (PromoCell, c-39215) at 5% CO2 and 37 °C. HUVEC were routinely tested for mycoplasma contamination. HUVEC were seeded into 24-well plates (at 1.5 × 10^4/well) 24 h prior to drug treatment. HUVEC were washed to remove cell debris and constitutively released EVs then pre-treated for 30 min in endothelial cell growth media with the appropriate inhibitor. After this, media was replaced with HEPES-buffered saline supplemented with glucose (0.9 mg/mL), CaCl2 (2 mM), A23187 (10 μM) and inhibitor for 10 min. Following stimulation, both the EV-rich medium and trypsinized endothelial cells were collected and stained with APC-conjugated anti-CD31 (eBioscience, ThermoFisher, UK). Samples were analysed using a BD Accuri C6 flow cytometer. APC fluorescence (FL4) was used to trigger event acquisition and identify endothelial (or endothelial-derived EV) events. to determine EV count and cellular PS exposure, respectively. PS-exposing endothelial-derived EVs were defined as CD31+/annexin V+ events that were smaller than 1 μm in an analogous manner to platelet-derived EVs.

**Endothelial viability**

To determine inhibitor toxicity, HUVEC were seeded in a 96-well clear-bottom plate at 1.5 × 10^4 cells/well, 24 h prior to treatment. Endothelial cells were treated as described above. The cell viability assay (Promega, UK G7572) was conducted according to the manufacturer’s instruction to evaluate the ATP content.

**Data presentation and statistical analysis**

Data are reported as mean ± standard error of mean (SEM) from at least five independent platelet preparations. N = 5 was chosen based on the mean and standard deviation of AnV+ EV release in preliminary experiments, in order to detect a 50% reduction with 80% power at p < 0.05. Data were compared using one-way or two-way repeat measures analysis of variance (RM-ANOVA), as appropriate, in GraphPad Prism v7. No samples were excluded from analysis. Concentration–response curves were fitted using a four-parameter logistical equation. This was also used to estimate pIC_{50} (i.e., −log(IC_{50}).

**Source of materials**

All reagents, including the 2-APB analogues, were obtained from Sigma Aldrich (Poole, Dorset, UK) unless otherwise stated. A23187 was from Acros Organics (Fisher Scientific, UK). 2-APB was from Cayman Chemicals (Cambridge Bioscience, Cambridge, UK). SAR-7334 and SN-6 were from Tocris (Bristol, UK). Calcein and BCECF were from ThermoFisher Scientific. Cal-520 was from AAT Bioquest (Sunnyvale CA, USA).

**Acknowledgements**

J.E.D. was supported by British Heart Foundation Project Grant PG/16/45/32152 to M.T.H. Work in Dr. Harper’s lab was also supported by Wellcome Trust Seed Award 200702/Z/16/Z and Royal Society Research Grant RG170381.

**Data availability**

The data are available from the corresponding author on reasonable request.

**Conflict of interest**

The authors declare that they have no conflict of interest.

**Publisher’s note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of this article (https://doi.org/10.1038/s41420-020-0244-9) contains supplementary material, which is available to authorized users.

**References**

1. Jackson, S. P. Arterial thrombosis-insidious, unpredictable and deadly. Nat. Med. 17, 1423–1436 (2011).
2. Huber, K. et al. Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold? Am. Heart J. 168, 611–621 (2014).
3. Protasiewicz, M., Szymkiewicz, P., Kulickowski, W., Mysiak, A. & Witkiewicz, W. Modern antiplatelet therapy—opportunities and risks. Adv. Clin. Exp. Med. 22, 875–885 (2013).
4. Suzuki, J., Umeda, M., Sims, P. J. & Nagata, S. Calcium-dependent phospholipid scrambling by TMEM16F. Nature 468, 834–838 (2010).
5. Fuji, T., Sakata, A., Nishimura, S., Eto, K. & Nagata, S. TMEM16F is required for phosphatidylserine exposure and microparticle release in activated mouse platelets. Proc. Natl Acad. Sci. USA 112, 12890–12895 (2015).
6. Millington-Burgess, S. L. & Harper, M. T. Gene of the issue: ANG6 and Scott Syndrome. Platelets https://doi.org/10.1080/09537104.2019.1698039 (2019).

7. Lhermusier, T., Chap, H. & Payastré, B. Platelet membrane phospholipid asymmetry: from the characterization of a scramblase activity to the identification of an essential protein mutated in Scott syndrome. J. Thromb. Haemost. 9, 1883–1891 (2011).

8. van Geffen, J. P., Swiernia, F. & Heemskerk, J. W. M. M. Platelets and coagulation in thrombus formation: aberrations in the Scott syndrome. Thromb. Res. 141, S12–S16 (2016).

9. Swiernia, F., Szechy, F. & Heemskerk, J. W. M. & van der Meyden, P. E. J. Integrating platelet and coagulation activation in fibronectin clot formation. Res. Pract. Thromb. Haemost. 2, 450–460 (2018).

10. Heemskerk, J. W. M. & Matalon, N. J. A. & Coseman, J. M. E. Platelet-based coagulation: different populations, different functions. J. Thromb. Haemost. 11, 2–16 (2013).

11. Vajen, T., Mause, S. F. & Koenen, R. R. Microvesicles from platelets: novel drivers of vascular inflammation. Thromb. Haemost. 114, 228–236 (2015).

12. Sun, C., Zhao, W. B., Chen, Y. & Hu, H. Y. Higher plasma concentrations of platelet-derived microparticles in patients with acute coronary syndrome: a systematic review and meta-analysis. Can. J. Cardiol. 32, 1325.e1–1325.e10 (2016).

13. Mavroudis, C. A. et al. Microparticles in acute coronary syndrome. Thromb. Res. 156, 109–116 (2017).

14. Preston, R. A. et al. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension 60, 2450–2455 (2016).

15. Cortez-Espinosa, N. et al. Platelets and platelet-derived microparticles as novel drivers of vascular inflammation. Thromb. Haemost. 113, 2061–2074 (2016).

16. Italiano, J. E., Mairuhu, A. T. A., Flammang, R. & Flamang, R. Clinical relevance of microparticles from platelets and megakaryocytes. Curr. Opin. Hematol. 17, 578–584 (2010).

17. Sims, P. J., Wiedemer, T., Esmen, C. T., Weiss, H. J. & Shattil, S. J. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J. Biol. Chem. 264, 17049–17057 (1989).

18. Fox, J. E. B., Austin, C. D., Reynolds, C. C. & Steffen, P. K. Evidence that agonist-induced activation of calpain causes the shedding of procoagulant-containing microvesicles from the membrane of aggregating platelets. J. Biol. Chem. 266, 13289–13295 (1991).

19. Bachelot-Laza, C. et al. Differential regulation of platelet aggregation and aminophospholipid exposure by calpain. Br. J. Haematol. 133, 419–426 (2006).

20. Wei, H., Malcor, J. & Harper, M. Lipid rafts are essential for release of phosphatidylserine-exposing extracellular vesicles from platelets. Sci. Rep. 8, 9987 (2018).

21. Finch, A. & Gardner, P. J. Thermochemistry of phenylboronic acid, diphenylborinic acid, and their arylhydrides. Trans. Faraday Soc. 62, 3514 (1966).

22. Dobrynina, Y. & Blackmore, P. 2-Aminooxothiolipid bovine directly inhibits store-operated calcium entry channels in human platelets. Mol. Pharmacol. 60, 541–552 (2001).

23. Harteneck, C. & Gollasch, M. Pharmacological modulation of diacylglycerol-sensitive TRPC3/6/7 channels. Curr. Pharm. Biotechnol. 12, 35–41 (2011).

24. Wei, M. et al. Molecular mechanisms underlying inhibition of STIM1-Orai1-mediated Ca2+ entry induced by 2-aminooxothiolipid bovine. Pfugers Arch. 468, 2061–2074 (2016).

25. Gilio, K. et al. Functional divergence of platelet protein kinase C (PKC) isoforms in thrombus formation on collagen. J. Biol. Chem. 285, 23408–23417 (2010).

26. Littlechild, R., Zadman, N., Khodaverdi, D. & Mason, M. J. Inhibition of iKCa3.1 by depolarisation and 2-aminothxydiphenyl borate (2-APB) during Ca2+ release activated Ca2+- (CRAC) entry in human erythroleukemia (HEL) cells: implications for the interpretation of 2-APB inhibition of CRAC entry. Cell Calcium 57, 76–88 (2015).

27. Wolfs, J. L. et al. Reversible inhibition of the platelet procoagulant response through manipulation of the Gardos channel. Blood 108, 2223–2228 (2006).

28. Jang, W. et al. Calpain cleaves phospholipid flippase ATP8A1 during apoptosis in platelets. Blood Adv. 3, 219–229 (2019).

29. Zhou, B. D., Guo, G., Zheng, L. M., Zhu, L. Y. & Gao, W. Microparticles as novel biomarkers and therapeutic targets in coronary heart disease. Chin. Med. J. 128, 267–272 (2015).

30. van der Poel, E. & Harrison, P. From platelet dust to gold dust: physiological importance and detection of platelet microvesicles. Platelets 28, 211–213 (2017).

31. Owens, A. & Mackman, N. Microparticles in hemostasis and thrombosis. Circ. Res. 108, 1294–1297 (2011).

32. Most, O., Josel, L., Freyssinet, J. M. & Tots, F. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler. Thromb. Vasc. Biol. 31, 15–26 (2011).

33. Diver, J. M., Sage, S. O. & Rosado, J. A. The inositol trisphosphate receptor antagonist 2-aminooxothiolipid bovine (2-APB) blocks Ca2+ entry channels in human platelets: cautions for its use in studying Ca2+ influx. Cell Calcium 30, 323–339 (2001).

34. Harper, M. T. & Poole, A. W. PKC inhibition markedly enhances Ca2+-signaling and phosphatidylserine exposure downstream of prostate-activated receptor-1 but not prostate-activated receptor-4 in human platelets. J. Thromb. Haemost. 9, 1599–1607 (2011).

35. Harper, M. T. et al. Transient receptor potential channels function as a coincidence signal detector mediating phosphatidylserine exposure. Sci. Signal. 6, ra50 (2013).

36. Harper, M. T. & Poole, A. W. Store-operated calcium entry and non-capacitative calcium entry have distinct roles in thrombin-induced calcium signalling in human platelets. Cell Calcium 50, 351–358 (2011).

37. Delfs, O., Mentz, P. & Chomienne, C. The boron-oxygen core of borinate esters is responsible for the store-operated calcium entry potentiation ability. BMC Pharmacol. 11, 1 (2011).

38. Baldwin, A. G. et al. Boron-Based Inhibitors of the NLRP3 Inflammasome. Cell Chem. Biol. 24, 1321–1335.e5 (2017).

39. MacKenzie, A. et al. Rapid secretion of interleukin-1β by microvesicle shedding. Immunity 15, 825–835 (2001).

40. Flammang, R. in Platelets and Megakaryocytes 273, 365–378 (Humana Press, 2004).

41. Chokshi, R., Fruasaha, P. & Kozak, J. A. 2-Aminooxothiolipid bovine inhibits TRPM7 channels through an intracellular acidification mechanism. Channels 6, 362–369 (2012).

42. Jardín, I., López, J. J., Pariente, J. A., Salido, G. M. & Rosado, J. A. Intracellular calcium release from human platelets: different messengers for multiple stores. Trends Cardiovasc. Med. 18, 57–61 (2008).

43. Sage, S. O., Pugh, N., Mason, M. J. & Harper, A. G. S. Monitoring the intracellular store Ca2+-concentration in agonist-stimulated intact human platelets by using Fluo-SN J. Thromb. Haemost. 9, 540–551 (2011).

44. Wei, H. & Harper, M. T. ABT-737 triggers caspase-dependent inhibition of platelet procoagulant extracellular vesicle release during apoptosis and secondary necrosis in vitro. Thromb. Haemost. 19, 1665–1674 (2019).

45. Schiro, A. et al. Endothelial microparticles as conveyors of information in atherosclerotic disease. Atherosclerosis 234, 295–302 (2014).